EDN1 and pulmonary arterial hypertension: ET-1 levels are markedly increased in almost all forms of pulmonary hypertension, and ET-1 receptor antagonists prevent and partially reverse the development of hypoxic pulmonary hypertension in animal models [22]–[30] and are now used clinically in the management of many forms of pulmonary hypertension [31].